Roche's Genentech Reveals Phase I Results Of Its Oral GLP-1 Receptor Agonist CT-996 For The Treatment Of People With Obesity
Portfolio Pulse from Benzinga Newsdesk
Roche's Genentech has revealed positive Phase I results for its oral GLP-1 receptor agonist CT-996, showing significant weight loss in patients with obesity. The treatment demonstrated a -7.3% weight loss compared to -1.2% in the placebo group, with a favorable safety and tolerability profile.
July 17, 2024 | 5:48 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roche's Genentech has announced positive Phase I results for its oral GLP-1 receptor agonist CT-996, showing significant weight loss in patients with obesity. The treatment demonstrated a -7.3% weight loss compared to -1.2% in the placebo group, with a favorable safety and tolerability profile.
The positive Phase I results for CT-996 indicate a potentially effective treatment for obesity, which could lead to further clinical trials and eventual market approval. This news is likely to boost investor confidence in Roche's innovative pipeline, positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100